aluates Reports

$ 0.0

Automative

Global Value-added Medicines (VAM) Market Research Report 2026

Published Date: 2026-01-22

Report Code: QYRE-Auto-33U18759

Global Value added Medicines VAM Market Research Report 2025

BUY CHAPTERS

Global Value-added Medicines (VAM) Market Research Report 2026

Code: QYRE-Auto-33U18759

Report

2026-01-22

Pages:111

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

MS Pharma

Rovi

ELPEN

Sandoz Inc

Adamed

TIEFENBACHER GROUP

Zentiva Group

Towa International

CNX Therapeutics

Colonis

Hyloris Pharmaceuticals SA

Value-added Medicines (VAM) Market Size

The global Value-added Medicines (VAM) market was valued at US$ 842 million in 2025 and is anticipated to reach US$ 1759 million by 2032, at a CAGR of 11.3% from 2026 to 2032.

Value-added Medicines (VAM) Market

Value-added medicines offer the medical world the opportunity to increase the quality of treatments as well as expand access to healthcare for more people. By improving the efficiency of the healthcare system, value-based healthcare contributes to its sustainability, addresses inefficiencies related to medicines, and offers economic advantages to all parties involved in medical treatments.Value-added medicines are drug products and treatments created using known molecules through a process known as drug repositioning. The purpose of these innovative medicines is to create improvements in the quality of patient care.Value-based treatment options give patients more agency to manage their ailments, leading to improved patient adherence, quality of life, and health outcomes. Likewise, improved treatments prevent medical conditions to escalate to serious levels. This lightens the burden that patients in critical condition put on healthcare systems, giving doctors and nurses some much-needed breathing space.

The North American market for Value-added Medicines (VAM) is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for Value-added Medicines (VAM) is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The global market for Value-added Medicines (VAM) in Hospital is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.

Major global companies of Value-added Medicines (VAM) include Zentiva Group, MS Pharma, Towa International, CNX Therapeutics, ROVI, Elpen, Sandoz AG, Colonis, Adamed, Hyloris Pharmaceuticals SA, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global Value-added Medicines (VAM) market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Value-added Medicines (VAM). The Value-added Medicines (VAM) market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Value-added Medicines (VAM) market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Value-added Medicines (VAM) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Value-added Medicines (VAM) Market Report

Report Metric	Details
Report Name	Value-added Medicines (VAM) Market
Accounted market size in 2025	US$ 842 million
Forecasted market size in 2032	US$ 1759 million
CAGR	11.3%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Chronic Disease Treatment Drugs Infectious Disease Treatment Drugs Tumor Treatment Drugs Other
Segment by Application	Hospital Clinic Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Zentiva Group, MS Pharma, Towa International, CNX Therapeutics, ROVI, Elpen, Sandoz AG, Colonis, Adamed, Hyloris Pharmaceuticals SA, TIEFENBACHER GROUP
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Value-added Medicines (VAM) companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Value-added Medicines (VAM) Market growing?

Ans: The Value-added Medicines (VAM) Market witnessing a CAGR of 11.3% during the forecast period 2026-2032.

What is the Value-added Medicines (VAM) Market size in 2032?

Ans: The Value-added Medicines (VAM) Market size in 2032 will be US$ 1759 million.

Who are the main players in the Value-added Medicines (VAM) Market report?

Ans: The main players in the Value-added Medicines (VAM) Market are Zentiva Group, MS Pharma, Towa International, CNX Therapeutics, ROVI, Elpen, Sandoz AG, Colonis, Adamed, Hyloris Pharmaceuticals SA, TIEFENBACHER GROUP

What are the Application segmentation covered in the Value-added Medicines (VAM) Market report?

Ans: The Applications covered in the Value-added Medicines (VAM) Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Value-added Medicines (VAM) Market report?

Ans: The Types covered in the Value-added Medicines (VAM) Market report are Chronic Disease Treatment Drugs, Infectious Disease Treatment Drugs, Tumor Treatment Drugs, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Value-added Medicines (VAM) Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Chronic Disease Treatment Drugs

1.2.3 Infectious Disease Treatment Drugs

1.2.4 Tumor Treatment Drugs

1.2.5 Other

1.3 Market by Application

1.3.1 Global Value-added Medicines (VAM) Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Value-added Medicines (VAM) Market Perspective (2021–2032)

2.2 Global Value-added Medicines (VAM) Growth Trends by Region

2.2.1 Global Value-added Medicines (VAM) Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Value-added Medicines (VAM) Historic Market Size by Region (2021–2026)

2.2.3 Value-added Medicines (VAM) Forecasted Market Size by Region (2027–2032)

2.3 Value-added Medicines (VAM) Market Dynamics

2.3.1 Value-added Medicines (VAM) Industry Trends

2.3.2 Value-added Medicines (VAM) Market Drivers

2.3.3 Value-added Medicines (VAM) Market Challenges

2.3.4 Value-added Medicines (VAM) Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Value-added Medicines (VAM) Players by Revenue

3.1.1 Global Top Value-added Medicines (VAM) Players by Revenue (2021–2026)

3.1.2 Global Value-added Medicines (VAM) Revenue Market Share by Players (2021–2026)

3.2 Global Top Value-added Medicines (VAM) Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Value-added Medicines (VAM) Revenue

3.4 Global Value-added Medicines (VAM) Market Concentration Ratio

3.4.1 Global Value-added Medicines (VAM) Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Value-added Medicines (VAM) Revenue in 2025

3.5 Global Key Players of Value-added Medicines (VAM) Head Offices and Areas Served

3.6 Global Key Players of Value-added Medicines (VAM), Products and Applications

3.7 Global Key Players of Value-added Medicines (VAM), Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Value-added Medicines (VAM) Breakdown Data by Type

4.1 Global Value-added Medicines (VAM) Historic Market Size by Type (2021–2026)

4.2 Global Value-added Medicines (VAM) Forecasted Market Size by Type (2027–2032)

5 Value-added Medicines (VAM) Breakdown Data by Application

5.1 Global Value-added Medicines (VAM) Historic Market Size by Application (2021–2026)

5.2 Global Value-added Medicines (VAM) Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Value-added Medicines (VAM) Market Size (2021–2032)

6.2 North America Value-added Medicines (VAM) Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Value-added Medicines (VAM) Market Size by Country (2021–2026)

6.4 North America Value-added Medicines (VAM) Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Value-added Medicines (VAM) Market Size (2021–2032)

7.2 Europe Value-added Medicines (VAM) Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Value-added Medicines (VAM) Market Size by Country (2021–2026)

7.4 Europe Value-added Medicines (VAM) Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Value-added Medicines (VAM) Market Size (2021–2032)

8.2 Asia-Pacific Value-added Medicines (VAM) Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Value-added Medicines (VAM) Market Size by Region (2021–2026)

8.4 Asia-Pacific Value-added Medicines (VAM) Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Value-added Medicines (VAM) Market Size (2021–2032)

9.2 Latin America Value-added Medicines (VAM) Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Value-added Medicines (VAM) Market Size by Country (2021–2026)

9.4 Latin America Value-added Medicines (VAM) Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Value-added Medicines (VAM) Market Size (2021–2032)

10.2 Middle East & Africa Value-added Medicines (VAM) Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Value-added Medicines (VAM) Market Size by Country (2021–2026)

10.4 Middle East & Africa Value-added Medicines (VAM) Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Zentiva Group

11.1.1 Zentiva Group Company Details

11.1.2 Zentiva Group Business Overview

11.1.3 Zentiva Group Value-added Medicines (VAM) Introduction

11.1.4 Zentiva Group Revenue in Value-added Medicines (VAM) Business (2021–2026)

11.1.5 Zentiva Group Recent Development

11.2 MS Pharma

11.2.1 MS Pharma Company Details

11.2.2 MS Pharma Business Overview

11.2.3 MS Pharma Value-added Medicines (VAM) Introduction

11.2.4 MS Pharma Revenue in Value-added Medicines (VAM) Business (2021–2026)

11.2.5 MS Pharma Recent Development

11.3 Towa International

11.3.1 Towa International Company Details

11.3.2 Towa International Business Overview

11.3.3 Towa International Value-added Medicines (VAM) Introduction

11.3.4 Towa International Revenue in Value-added Medicines (VAM) Business (2021–2026)

11.3.5 Towa International Recent Development

11.4 CNX Therapeutics

11.4.1 CNX Therapeutics Company Details

11.4.2 CNX Therapeutics Business Overview

11.4.3 CNX Therapeutics Value-added Medicines (VAM) Introduction

11.4.4 CNX Therapeutics Revenue in Value-added Medicines (VAM) Business (2021–2026)

11.4.5 CNX Therapeutics Recent Development

11.5 ROVI

11.5.1 ROVI Company Details

11.5.2 ROVI Business Overview

11.5.3 ROVI Value-added Medicines (VAM) Introduction

11.5.4 ROVI Revenue in Value-added Medicines (VAM) Business (2021–2026)

11.5.5 ROVI Recent Development

11.6 Elpen

11.6.1 Elpen Company Details

11.6.2 Elpen Business Overview

11.6.3 Elpen Value-added Medicines (VAM) Introduction

11.6.4 Elpen Revenue in Value-added Medicines (VAM) Business (2021–2026)

11.6.5 Elpen Recent Development

11.7 Sandoz AG

11.7.1 Sandoz AG Company Details

11.7.2 Sandoz AG Business Overview

11.7.3 Sandoz AG Value-added Medicines (VAM) Introduction

11.7.4 Sandoz AG Revenue in Value-added Medicines (VAM) Business (2021–2026)

11.7.5 Sandoz AG Recent Development

11.8 Colonis

11.8.1 Colonis Company Details

11.8.2 Colonis Business Overview

11.8.3 Colonis Value-added Medicines (VAM) Introduction

11.8.4 Colonis Revenue in Value-added Medicines (VAM) Business (2021–2026)

11.8.5 Colonis Recent Development

11.9 Adamed

11.9.1 Adamed Company Details

11.9.2 Adamed Business Overview

11.9.3 Adamed Value-added Medicines (VAM) Introduction

11.9.4 Adamed Revenue in Value-added Medicines (VAM) Business (2021–2026)

11.9.5 Adamed Recent Development

11.10 Hyloris Pharmaceuticals SA

11.10.1 Hyloris Pharmaceuticals SA Company Details

11.10.2 Hyloris Pharmaceuticals SA Business Overview

11.10.3 Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Introduction

11.10.4 Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Business (2021–2026)

11.10.5 Hyloris Pharmaceuticals SA Recent Development

11.11 TIEFENBACHER GROUP

11.11.1 TIEFENBACHER GROUP Company Details

11.11.2 TIEFENBACHER GROUP Business Overview

11.11.3 TIEFENBACHER GROUP Value-added Medicines (VAM) Introduction

11.11.4 TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Business (2021–2026)

11.11.5 TIEFENBACHER GROUP Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

MS Pharma

Rovi

ELPEN

Sandoz Inc

Adamed

TIEFENBACHER GROUP

Zentiva Group

Towa International

CNX Therapeutics

Colonis

Hyloris Pharmaceuticals SA

List of Tables

Table 1. Global Value-added Medicines (VAM) Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Chronic Disease Treatment Drugs

Table 3. Key Players of Infectious Disease Treatment Drugs

Table 4. Key Players of Tumor Treatment Drugs

Table 5. Key Players of Other

Table 6. Global Value-added Medicines (VAM) Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 7. Global Value-added Medicines (VAM) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 8. Global Value-added Medicines (VAM) Market Size by Region (US$ Million), 2021–2026

Table 9. Global Value-added Medicines (VAM) Market Share by Region (2021–2026)

Table 10. Global Value-added Medicines (VAM) Forecasted Market Size by Region (US$ Million), 2027–2032

Table 11. Global Value-added Medicines (VAM) Market Share by Region (2027–2032)

Table 12. Value-added Medicines (VAM) Market Trends

Table 13. Value-added Medicines (VAM) Market Drivers

Table 14. Value-added Medicines (VAM) Market Challenges

Table 15. Value-added Medicines (VAM) Market Restraints

Table 16. Global Value-added Medicines (VAM) Revenue by Players (US$ Million), 2021–2026

Table 17. Global Value-added Medicines (VAM) Market Share by Players (2021–2026)

Table 18. Global Top Value-added Medicines (VAM) Players by Tier (Tier 1, Tier 2, and Tier 3), based on Value-added Medicines (VAM) Revenue, 2025

Table 19. Ranking of Global Top Value-added Medicines (VAM) Companies by Revenue (US$ Million) in 2025

Table 20. Global 5 Largest Players Market Share by Value-added Medicines (VAM) Revenue (CR5 and HHI), 2021–2026

Table 21. Global Key Players of Value-added Medicines (VAM), Headquarters and Area Served

Table 22. Global Key Players of Value-added Medicines (VAM), Products and Applications

Table 23. Global Key Players of Value-added Medicines (VAM), Date of General Availability (GA)

Table 24. Mergers and Acquisitions, Expansion Plans

Table 25. Global Value-added Medicines (VAM) Market Size by Type (US$ Million), 2021–2026

Table 26. Global Value-added Medicines (VAM) Revenue Market Share by Type (2021–2026)

Table 27. Global Value-added Medicines (VAM) Forecasted Market Size by Type (US$ Million), 2027–2032

Table 28. Global Value-added Medicines (VAM) Revenue Market Share by Type (2027–2032)

Table 29. Global Value-added Medicines (VAM) Market Size by Application (US$ Million), 2021–2026

Table 30. Global Value-added Medicines (VAM) Revenue Market Share by Application (2021–2026)

Table 31. Global Value-added Medicines (VAM) Forecasted Market Size by Application (US$ Million), 2027–2032

Table 32. Global Value-added Medicines (VAM) Revenue Market Share by Application (2027–2032)

Table 33. North America Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 34. North America Value-added Medicines (VAM) Market Size by Country (US$ Million), 2021–2026

Table 35. North America Value-added Medicines (VAM) Market Size by Country (US$ Million), 2027–2032

Table 36. Europe Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 37. Europe Value-added Medicines (VAM) Market Size by Country (US$ Million), 2021–2026

Table 38. Europe Value-added Medicines (VAM) Market Size by Country (US$ Million), 2027–2032

Table 39. Asia-Pacific Value-added Medicines (VAM) Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 40. Asia-Pacific Value-added Medicines (VAM) Market Size by Region (US$ Million), 2021–2026

Table 41. Asia-Pacific Value-added Medicines (VAM) Market Size by Region (US$ Million), 2027–2032

Table 42. Latin America Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 43. Latin America Value-added Medicines (VAM) Market Size by Country (US$ Million), 2021–2026

Table 44. Latin America Value-added Medicines (VAM) Market Size by Country (US$ Million), 2027–2032

Table 45. Middle East & Africa Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 46. Middle East & Africa Value-added Medicines (VAM) Market Size by Country (US$ Million), 2021–2026

Table 47. Middle East & Africa Value-added Medicines (VAM) Market Size by Country (US$ Million), 2027–2032

Table 48. Zentiva Group Company Details

Table 49. Zentiva Group Business Overview

Table 50. Zentiva Group Value-added Medicines (VAM) Product

Table 51. Zentiva Group Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026

Table 52. Zentiva Group Recent Development

Table 53. MS Pharma Company Details

Table 54. MS Pharma Business Overview

Table 55. MS Pharma Value-added Medicines (VAM) Product

Table 56. MS Pharma Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026

Table 57. MS Pharma Recent Development

Table 58. Towa International Company Details

Table 59. Towa International Business Overview

Table 60. Towa International Value-added Medicines (VAM) Product

Table 61. Towa International Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026

Table 62. Towa International Recent Development

Table 63. CNX Therapeutics Company Details

Table 64. CNX Therapeutics Business Overview

Table 65. CNX Therapeutics Value-added Medicines (VAM) Product

Table 66. CNX Therapeutics Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026

Table 67. CNX Therapeutics Recent Development

Table 68. ROVI Company Details

Table 69. ROVI Business Overview

Table 70. ROVI Value-added Medicines (VAM) Product

Table 71. ROVI Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026

Table 72. ROVI Recent Development

Table 73. Elpen Company Details

Table 74. Elpen Business Overview

Table 75. Elpen Value-added Medicines (VAM) Product

Table 76. Elpen Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026

Table 77. Elpen Recent Development

Table 78. Sandoz AG Company Details

Table 79. Sandoz AG Business Overview

Table 80. Sandoz AG Value-added Medicines (VAM) Product

Table 81. Sandoz AG Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026

Table 82. Sandoz AG Recent Development

Table 83. Colonis Company Details

Table 84. Colonis Business Overview

Table 85. Colonis Value-added Medicines (VAM) Product

Table 86. Colonis Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026

Table 87. Colonis Recent Development

Table 88. Adamed Company Details

Table 89. Adamed Business Overview

Table 90. Adamed Value-added Medicines (VAM) Product

Table 91. Adamed Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026

Table 92. Adamed Recent Development

Table 93. Hyloris Pharmaceuticals SA Company Details

Table 94. Hyloris Pharmaceuticals SA Business Overview

Table 95. Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Product

Table 96. Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026

Table 97. Hyloris Pharmaceuticals SA Recent Development

Table 98. TIEFENBACHER GROUP Company Details

Table 99. TIEFENBACHER GROUP Business Overview

Table 100. TIEFENBACHER GROUP Value-added Medicines (VAM) Product

Table 101. TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Business (US$ Million), 2021–2026

Table 102. TIEFENBACHER GROUP Recent Development

Table 103. Research Programs/Design for This Report

Table 104. Key Data Information from Secondary Sources

Table 105. Key Data Information from Primary Sources

Table 106. Authors List of This Report

List of Figures

Figure 1. Value-added Medicines (VAM) Picture

Figure 2. Global Value-added Medicines (VAM) Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Value-added Medicines (VAM) Market Share by Type: 2025 vs 2032

Figure 4. Chronic Disease Treatment Drugs Features

Figure 5. Infectious Disease Treatment Drugs Features

Figure 6. Tumor Treatment Drugs Features

Figure 7. Other Features

Figure 8. Global Value-added Medicines (VAM) Market Size by Application (US$ Million), 2021–2032

Figure 9. Global Value-added Medicines (VAM) Market Share by Application: 2025 vs 2032

Figure 10. Hospital Case Studies

Figure 11. Clinic Case Studies

Figure 12. Other Case Studies

Figure 13. Value-added Medicines (VAM) Report Years Considered

Figure 14. Global Value-added Medicines (VAM) Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 15. Global Value-added Medicines (VAM) Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 16. Global Value-added Medicines (VAM) Market Share by Region: 2025 vs 2032

Figure 17. Global Value-added Medicines (VAM) Market Share by Players in 2025

Figure 18. Global Value-added Medicines (VAM) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 19. The Top 10 and 5 Players Market Share by Value-added Medicines (VAM) Revenue in 2025

Figure 20. North America Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 21. North America Value-added Medicines (VAM) Market Share by Country (2021–2032)

Figure 22. United States Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. Canada Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 24. Europe Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 25. Europe Value-added Medicines (VAM) Market Share by Country (2021–2032)

Figure 26. Germany Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. France Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. U.K. Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Italy Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Russia Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Ireland Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Asia-Pacific Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Asia-Pacific Value-added Medicines (VAM) Market Share by Region (2021–2032)

Figure 34. China Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Japan Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. South Korea Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Southeast Asia Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. India Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Australia & New Zealand Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Latin America Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Latin America Value-added Medicines (VAM) Market Share by Country (2021–2032)

Figure 42. Mexico Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Brazil Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Middle East & Africa Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Middle East & Africa Value-added Medicines (VAM) Market Share by Country (2021–2032)

Figure 46. Israel Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Saudi Arabia Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. UAE Value-added Medicines (VAM) Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Zentiva Group Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)

Figure 50. MS Pharma Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)

Figure 51. Towa International Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)

Figure 52. CNX Therapeutics Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)

Figure 53. ROVI Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)

Figure 54. Elpen Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)

Figure 55. Sandoz AG Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)

Figure 56. Colonis Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)

Figure 57. Adamed Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)

Figure 58. Hyloris Pharmaceuticals SA Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)

Figure 59. TIEFENBACHER GROUP Revenue Growth Rate in Value-added Medicines (VAM) Business (2021–2026)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Virtual Reality in Medicine and Healthcare Market Insights Forecast to 2030

Global Integrative Health or Complementary and Alternative Medicine Market Research Report 2024

Global Virtual Hospital Market Research Report 2025

Global Pharma 4 0 Market Research Report 2025

Global Pain Management Drugs Devices Market Research Report 2025

Global Virtual Medical Assistant Service Market Research Report 2025

Global Online Medical Market Research Report 2024

Global Pharma CRM Software Market Research Report 2024

Pharma and Healthcare Social Media Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Medication Management System Market Research Report 2024

Global Postoperative Pain Therapeutics Market Insights Forecast to 2030

Global Intravenous Packaging Market Research Report 2025

Global Value added Medicines VAM Development Service Market Research Report 2025

Value Based Healthcare Services Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Ventilator Associated Pneumonia VAP Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Medication Management Market Insights Forecast to 2030

PMMA Healthcare Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Pharma and Health Care Market Research Report 2024

Global Regenerative Medicine Products Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions